Oncological outcomes after piecemeal endoscopic mucosal resection of large non-pedunculated colorectal polyps with covert submucosal invasive cancer.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
12 2022
Historique:
received: 19 11 2020
accepted: 25 02 2022
pubmed: 9 3 2022
medline: 10 11 2022
entrez: 8 3 2022
Statut: ppublish

Résumé

Management of covert submucosal invasive cancer (SMIC) discovered after piecemeal endoscopic mucosal resection (pEMR) of large (>20 mm) non-pedunculated colorectal polyps is challenging. The residual cancer risk is largely unknown. We sought to evaluate this in a large tertiary referral cohort. Cases of covert SMIC following pEMR were identified and followed. Oncological outcomes after surgery were divided based on residual intramural cancer, lymph node metastases (LNM) or both. Risk factors for residual intramural cancer and LNM were analysed based on the original pEMR histological variables. Risk parameters were analysed with respect to low and high-risk variables for residual intramural cancer and LNM. Among 3372 cases of large non-pedunculated colorectal polyps, 143 cases of covert SMIC (4.2%) were identified. 109 underwent surgical resection. Histological analysis of pEMR histology was available in 98 of 109 (90%) cases. 62 cases (63%) had no residual malignancy. 36 cases had residual malignancy (residual intramural cancer n=24; LNM n=5; both n=7). All cases of residual intramural cancer could be identified by a R1 histological deep margin. Cases with poor differentiation (PD) and/or lymphovascular invasion (LVI) had a high risk of LNM (12/33), with a very low risk without these criteria (<1%; 0/65). Cases at low risk for LNM with R0 deep margin have a low risk of residual intramural cancer (<1%; 0/35). The majority of cases of large non-pedunculated colorectal polyps with covert SMIC following pEMR will have no residual malignancy. The risk of residual malignancy can be ascertained from three key variables: PD, LVI and R1 deep margin.

Identifiants

pubmed: 35256387
pii: gutjnl-2020-323666
doi: 10.1136/gutjnl-2020-323666
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2481-2488

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Dave J Gibson (DJ)

Gastroenterology, Alfred Health, Melbourne, Victoria, Australia D.Gibson@alfred.org.au.

Mayenaaz Sidhu (M)

Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.
Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.

Simon Zanati (S)

Gastroenterology, Western Health, Footscray, Victoria, Australia.

David J Tate (DJ)

Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.

Dileep Mangira (D)

Gastroenterology, Western Health, Footscray, Victoria, Australia.

Alan Moss (A)

Department of Gastroenterology, Western Hospital, Footscray, Victoria, Australia.

Rajvinder Singh (R)

Gastroenterology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.

Luke F Hourigan (LF)

Gastroenterology, Greenslopes Private Hospital, Brisbane, Queensland, Australia.

Spiro Raftopoulos (S)

Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Alan Pham (A)

Anatomical Pathology, Alfred Hospital, Melbourne, Victoria, Australia.

Phil Kostos (P)

Pathology, Western Health, Footscray, Victoria, Australia.

M Priyanthi Kumarasinghe (MP)

Department of Anatomical Pathology, PathWest, QEII Medical Centre, Perth, Western Australia, Australia.

Andrew Ruszkiewicz (A)

Pathology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.

Duncan McLeod (D)

Institute of Clinical Pathology and Medical Research, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Australia, Westmead Hospital, Westmead, New South Wales, Australia.

Gregor J E Brown (GJE)

Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.

Michael J Bourke (MJ)

Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.
Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH